IN2015DN00438A - - Google Patents

Info

Publication number
IN2015DN00438A
IN2015DN00438A IN438DEN2015A IN2015DN00438A IN 2015DN00438 A IN2015DN00438 A IN 2015DN00438A IN 438DEN2015 A IN438DEN2015 A IN 438DEN2015A IN 2015DN00438 A IN2015DN00438 A IN 2015DN00438A
Authority
IN
India
Prior art keywords
periodontitis
present disclosure
diseases associated
describes methods
screening
Prior art date
Application number
Other languages
English (en)
Inventor
John D Lambris
George Hajishengallis
Original Assignee
Univ Pennsylvania
Univ Louisville Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Univ Louisville Res Found filed Critical Univ Pennsylvania
Publication of IN2015DN00438A publication Critical patent/IN2015DN00438A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4716Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/18Dental and oral disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
IN438DEN2015 2012-06-20 2013-06-19 IN2015DN00438A (enrdf_load_html_response)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662022P 2012-06-20 2012-06-20
US13/801,096 US9579360B2 (en) 2012-06-20 2013-03-13 Methods of treating or preventing periodontitis and diseases associated with periodontitis
PCT/US2013/046599 WO2013192319A1 (en) 2012-06-20 2013-06-19 Methods of treating or preventing periodontitis and diseases associated with periodontitis

Publications (1)

Publication Number Publication Date
IN2015DN00438A true IN2015DN00438A (enrdf_load_html_response) 2015-06-19

Family

ID=49769337

Family Applications (1)

Application Number Title Priority Date Filing Date
IN438DEN2015 IN2015DN00438A (enrdf_load_html_response) 2012-06-20 2013-06-19

Country Status (8)

Country Link
US (2) US9579360B2 (enrdf_load_html_response)
EP (1) EP2863949B1 (enrdf_load_html_response)
JP (1) JP6363595B2 (enrdf_load_html_response)
CN (1) CN104640567A (enrdf_load_html_response)
AU (1) AU2013277217B2 (enrdf_load_html_response)
CA (1) CA2877299C (enrdf_load_html_response)
IN (1) IN2015DN00438A (enrdf_load_html_response)
WO (1) WO2013192319A1 (enrdf_load_html_response)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2766755T3 (es) * 2011-09-07 2020-06-15 Univ Pennsylvania Análogos de compstatina con propiedades farmacocinéticas mejoradas
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
EP3110423A4 (en) 2014-02-25 2017-09-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of complement mediated disorders
KR101981532B1 (ko) 2014-06-12 2019-09-02 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
TWI745320B (zh) 2015-12-16 2021-11-11 美商Ra製藥公司 補體活性之調節劑
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
FI3985002T3 (fi) 2017-03-01 2025-07-30 Achillion Pharmaceuticals Inc Aryyli-, heteroaryyli- ja heterosyklisiä lääkeyhdisteitä sairauksien hoitoon
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3661493A4 (en) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. TREATMENT DIET FOR THE TREATMENT OF PAROXYSTIC NOCTURAL HEMOGLOBINURIA
RU2020117578A (ru) 2017-12-04 2022-01-14 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
US20200316163A1 (en) * 2017-12-15 2020-10-08 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
HUE057693T2 (hu) 2018-04-06 2022-05-28 Univ Pennsylvania Fokozott oldhatóságú és javított farmakokinetikai tulajdonságú kompsztatin analógok
KR20210057086A (ko) 2018-09-06 2021-05-20 아칠리온 파르마세우티칼스 인코포레이티드 다니코판의 형태체 형태
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
US11807627B2 (en) 2018-09-25 2023-11-07 Achillon Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
AU2019406830A1 (en) 2018-12-17 2021-07-08 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
TW202100179A (zh) 2019-03-08 2021-01-01 美商Ra製藥公司 補體活性之調節劑
EP3947352A1 (en) 2019-03-29 2022-02-09 RA Pharmaceuticals, Inc. Complement modulators and related methods
EP3958842A1 (en) 2019-04-24 2022-03-02 RA Pharmaceuticals, Inc. Compositions and methods for modulating complement activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270365A (en) 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
JP2001294536A (ja) * 2000-04-12 2001-10-23 Sunstar Inc 歯周病予防・治療剤
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
PT1928454E (pt) * 2005-05-10 2014-12-04 Intermune Inc Derivativos da piridona para modulação do sistema de proteína quinase ativada pelo stress
EP2979729A3 (en) * 2007-02-05 2016-05-11 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
DK2424557T3 (en) * 2009-05-01 2018-01-22 Univ Pennsylvania MODIFIED COMPSTATIN WITH PEPTID BACKBONE AND C-TERMINAL MODIFICATIONS
WO2010132954A1 (en) 2009-05-21 2010-11-25 Oral Health Australia Pty Ltd Method of treating periodontal disease by administering antagonists of par-2
CA2774008C (en) * 2009-09-23 2017-06-20 The Regents Of The University Of Colorado, A Body Corporate Toll-like receptor modulators and uses thereof
AU2011207441A1 (en) 2010-01-22 2012-08-09 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
US10627412B2 (en) * 2010-03-17 2020-04-21 Kagoshima University Periodontal-disease-specific peptide, and treatment and diagnosis of periodontal disease using same
US10039802B2 (en) * 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
ES2766755T3 (es) * 2011-09-07 2020-06-15 Univ Pennsylvania Análogos de compstatina con propiedades farmacocinéticas mejoradas
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis

Also Published As

Publication number Publication date
US20130344082A1 (en) 2013-12-26
JP6363595B2 (ja) 2018-07-25
US9579360B2 (en) 2017-02-28
AU2013277217A2 (en) 2015-01-22
AU2013277217B2 (en) 2018-03-08
EP2863949A1 (en) 2015-04-29
EP2863949A4 (en) 2016-03-02
US20170202935A1 (en) 2017-07-20
US10668135B2 (en) 2020-06-02
CN104640567A (zh) 2015-05-20
JP2015523999A (ja) 2015-08-20
CA2877299A1 (en) 2013-12-27
CA2877299C (en) 2022-07-12
WO2013192319A1 (en) 2013-12-27
EP2863949B1 (en) 2019-01-23
AU2013277217A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
IN2015DN00438A (enrdf_load_html_response)
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
PH12016502167A1 (en) Hdl theraphy markers
MX365614B (es) Composiciones utiles para tratar trastornos relacionados con kit.
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
GB201103062D0 (en) Method
MX2014010481A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
JOP20140141B1 (ar) استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
MX2021011946A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
IN2014DN06792A (enrdf_load_html_response)
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
PL3082831T3 (pl) Kompozycje oparte na metylocyklodekstrynach do leczenia i/lub zapobiegania chorobom poprzez podwyższenie poziomu cholesterolu HDL
MX2020002544A (es) Sales de glicopirrolato.
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
EP3065768A4 (en) Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation
PL2792364T3 (pl) Kompozycja do zapobiegania lub do leczenia kaca
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
MX2015007518A (es) Metodos para tratar el prurito.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX2013007603A (es) Antagonistas de hedgehog que tienen residuos que se unen al zinc.
MX2015006337A (es) Metodos y composiciones para tratar enfermedades neurodegenerativas.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
IN2014DN06738A (enrdf_load_html_response)